In conclusion, we uncover a novel role of HNK as an effective leptin-antagonist that inhibits leptin-induced growth of breast cancer cells in vitro and in vivo, which involves activation of miR-34a facilitating HNK-mediated inhibition of Wnt1-MTA1-β-catenin axis. Here, LEP is linked to breast cancer.